OncoMatch/Clinical Trials/NCT06572813
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Is NCT06572813 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Bortezomib and Sintilimab for pancreas cancer.
Treatment: Bortezomib · Sintilimab · mFOLFIRINOX — This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in metastatic pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: Gemcitabine-based chemotherapy as first line allowed if progressed
Never receive any systematic treatment or Progression after fisrt line Gemcitabine base chemotherapy
Cannot have received: chemotherapy
History of receiving chemotherapy within 2 weeks
Cannot have received: radiation therapy
History of radiotherapy and molecular target therapy within 2 weeks
Cannot have received: targeted therapy
History of radiotherapy and molecular target therapy within 2 weeks
Lab requirements
Kidney function
Serum creatinine level is normal
Liver function
serum total bilirubin level is less than 1.5 x ULN; ALT and AST are less than 2 x ULN
Serum creatinine level is normal, and serum total bilirubin level is less than 1.5 x ULN. ALT and AST are less than 2 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06572813 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, chemotherapy, radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages